LC–MS/MS determination and pharmacokinetic study of columbianadin in rat plasma after intravenous administration of pure columbianadin by Yan-xu Chang et al.
Chang et al. Chemistry Central Journal  2014 8:64 
DOI 10.1186/s13065-014-0064-1RESEARCH ARTICLE Open AccessLC ? MS/MS determination and pharmacokinetic
study of columbianadin in rat plasma after
intravenous administration of pure
columbianadin
Yan-xu Chang1,2*, Chun-peng Wang1, Jin Li1,2, Yang Bai1, Qian Luo1, Jun He1, Bing Lu1, Tao Wang1,
Bo-li Zhang1,2 and Xiu-mei Gao1,2*Abstract
Background: Columbianadin, one of the active coumarins, is isolated from Radix Angelicae pubescentis which has
been used as a traditional Chinese medicine for the treatment of rheumatic diseases for thousands of years. A fast
and sensitive method is required for the determination of columbianadin for pharmacokinetic studies. Liquid
chromatography ? tandem mass spectrometry (LC-MS/MS) method is a preeminent analytical tool for rapid
biomedical analysis.
Results: A sensitive LC-MS/MS method has been validated to determine the concentration of columbianadin in
rat plasma after intravenous administration of columbianadin (1, 2.5 and 5 mg kg−1). Liquid-liquid extraction was
used to extract columbianadin from the rat plasma. Bergapten was selected as an internal standard (IS). The separations
were performed on an Eclipse plus C18 column (4.6 ? 100 mm, 1.8 μm) with ammonium acetate aqueous solution
(1 mmol L−1) and acetonitrile as the mobile phase. The flow rate was set at 0.300 mL min−1. Quantification was
performed using multiple reaction monitoring (MRM) mode to monitor transitions of m/z 329.3→ 229.3 for
columbianadin and m/z 217.2→ 202.2 for IS at positive ionization mode. The calibration curve was linear over the
concentration range of 4 ? 20000 ng mL−1 with a correlation coefficient (r) of 0.996 or better. The precision of
intra- and inter-batch assays ranged from 4.02 to 7.33% and accuracies determined at three concentrations
ranged between 91.9% and 106%. The lower limit of quantification was about 4 ng mL−1.
Conclusion: The proposed LC-MS/MS method is simple, rapid and highly sensitive so that it could be used to
evaluate pharmacokinetic properties of columbianadin in rat plasma after intravenous administration.
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Radix Angelicae pubescentis, a famous traditional Chinese
medicine, is used to treat musculoskeletal, waist and knee
pains, cold, dampness and headache [1]. Columbianadin,
which is an active coumarin, was selected as one of the
markers to evaluate the quality control of Radix Angelicae
pubescentis [2]. Recently, columbianadin was reported to* Correspondence: tcmcyx@126.com; gaoxiumei@tjutcm.edu.cn
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unless otherwise stated.exhibit anti-inflammatory as well as analgesic activities in
mice in vivo [3]. It could reduce iNOS in activated cells
stimulated with bacterial lipopolysaccharide [4-6]. It has
also been reported that columbianadin has calcium
channel blocking activity [7,8] and an automated Ca2+
uptake using GH4C1 cells in vitro [9,10]. Columbianadin
has significant bioactivity to inhibit rat platelet aggregation
induced by ADP in vitro. In addition, columbianadin
showed obvious antitumor activity that inhibited human
nasopharyngeal carcinoma cell line KB, human leukemia
cell line HL-60 [11] and human bladder carcinoma celln Open Access article distributed under the terms of the Creative Commons
org/licenses/by/4.0), which permits unrestricted use, distribution, and
riginal work is properly credited. The Creative Commons Public Domain
rg/publicdomain/zero/1.0/) applies to the data made available in this article,
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columbianadin has received extensive interest and in-
vestigation. It was demonstrated that columbianadin
could be absorbed into bloodstream by the intestinal
absorption and transportation of columbianadin after
the pass intestine perfusion [13].
Currently, only a few pharmacokinetic studies have
been conducted for the determination of columbianadin
in rat plasma. A high-performance liquid chromatog-
raphy (HPLC) with UV detection has been developed for
determination of columbianadin in rat plasma with a
lower limit of quantification of 0.10 μg mL−1 [14]. How-
ever, this method needs large volumes of organic solvent,
while having low sensitivity. Compared with traditional
HPLC analysis, liquid chromatography- tandem mass
spectrometry (LC-MS/MS) methods might provide sig-
nificant improvements in terms of method sensitivity.
The purpose of the present study was to develop and
validate a highly sensitive, rapid and specific method
based on LC-MS/MS for the quantification of columbia-
nadin in rat plasma. The method was successfully used
for the pharmacokinetic study of columbianadin in rats
after intravenous administration.
Results and discussion
Optimization of the chromatographic conditions
In terms of resolution and sensitive signal of analyte,
several factors including the mobile phase, type of col-
umn, gradient elution type and flow rate were optimized.
Finally, ammonium acetate aqueous solution (1 mmol L−1)Figure 1 Representative MRM chromatograms of the columbianadin
the columbianadin at LLOQ, and (c) plasma sample at 30 min after inand acetonitrile were optimized as the mobile phase
when the separation was performed on an Eclipse
plus C18 column (4.6 ? 100 mm, 1.8 μm). Basing on
this condition, the shorter chromatographic time, peak
sharpness and sensitive signal were obtained for columbia-
nadin and IS. It was found that ammonium acetate, which
was added to mobile phase, could significantly improve
the ESI efficiency and enhance response of columbianadin.
This result was consistent with previous studies [15].
Method validation
Specificity and sensitivity
Representative chromatograms of blank plasma, plasma
spiked with columbianadin and internal standard (IS)
and real plasma sample after intravenous administration
of columbianadin, respectively, are given in Figure 1. It
was observed that the analyte was well separated and no
interferences were detected from endogenous substances
or metabolites at the retention time of columbianadin or
IS. The lower limit of quantification (LLOQ) of columbia-
nadin in rat plasma was 4 ng mL−1 and the RSD was 2.3%.
The limit of detection of columbianadin in rat plasma was
1.6 ng mL−1. Compared with a previous HPLC method
[14], the new LC-MS/MS method might significantly im-
prove sensitivity of determinations.
Linearity
In order to obtain a good linear regression analysis of
columbianadin, the method was operated by plotting the
peak area ratio of columbianadin to IS (Y) versus analyteand IS: (a) blank plasma sample, (b) blank plasma sample spiked
travenous administrated of 5 mg kg−1 columbianadin.
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tion curves showed good linearity over the concentration
range of 4-20000 ng mL−1. The regression equation was
as follows: Y = 0.0243X + 0.0898 (r2 = 0.9962). It exhib-
ited a good linearity of columbianadin.
Accuracy and precision
The accuracy and precision of inter- and intra-batches
were assessed by analyzing six replicate QC samples for
each concentration of 20, 1000 and 10000 ng mL−1 re-
spectively. The data is presented in Table 1. It can be
seen that the RSDs of inter- and intra-batches were
below 7.73%, and accuracies of the intra- and inter-
batch assays ranged from 91.9% to 106%. The results of
intra- and inter-batch analysis indicated that the estab-
lished method was accurate and reliable.
Recovery, matrix effect and stability
Liquid? liquid extraction with ethyl acetate was employed
to extract eight coumarins from rat plasma in our previ-
ous research [16]. Because the chemical structure of
columbianadin is similar with those of the eight couma-
rins, the liquid? liquid extraction with ethyl acetate was
also selected to extract columbianadin from rat plasma.
Bergapten was selected as the IS to determine columbia-
nadin in rat plasma after intravenous administration. The
extraction recoveries of columbianadin were assessed by
analyzing six replicate QC samples at three different levels.
The results are shown in Table 1. It can be seen that the
mean extraction recoveries of columbianadin at three dif-
ferent levels were within the range of 81.4-102% and RSDs
were within the range of 6.19-9.86% for extraction recov-
eries. The recovery and RSD for extraction recoveries of
IS were 94.9% and 3.07%, respectively. It was concluded
that liquid-liquid extraction method with ethyl acetate
could be used to extract columbianadin from the rat
plasma.
The matrix often processed significant interference be-
tween the analyte and the endogenous co-eluents and af-
fected the accuracy of analysis results. In this study, the
matrix effect of columbianadin in rat plasma (Table 1)
ranged from 85.6% to 99.7% at the three level QC sam-








Mean RSD Mean RSD Remains R
(%) (%) (%) (%) (%) (
20 102 9.86 99.7 11.9 97.3 8
1000 85.5 8.71 85.6 5.66 102 1
10000 81.4 6.19 90.9 9.20 101 712%. The above results indicated that there was no ion
suppression or enhancement for columbianadin inter-
fered from the rat plasma matrix.
QC samples of columbianadin at three concentrations
(20, 1000 and 10000 ng/mL) were used for stability ex-
periments. Results of freeze/thaw stability, autosampler
stability and long-term stability are shown in Table 1. It
was found that the remains of columbianadin were
within the range of 97.3-102%, 92.6-110% and 90.0-
99.2% at three QC levels following freeze-thaw cycles,
at −20?C for 2 weeks and at autosampler for 24 h, re-
spectively. These results indicated that the stability of
QC samples at −20?C for 2 weeks, freeze/thaw stability
and post-preparative stability at room temperature for
24 h were acceptable.
Pharmacokinetic study
The established LC-MS/MS method was applied to phar-
macokinetic studies following the intravenous administra-
tion of columbianadin at the dose of 1, 2.5 and 5 mg kg−1,
respectively. The plasma concentration? time profile of
columbianadin in rats is shown in Figure 2. It was found
that the two-compartment model was the best fit pharma-
cokinetic model to estimate the pharmacokinetic parame-
ters. The pharmacokinetic parameters of columbianadin
are listed in Table 2. The distribution half-life(T1/2α) were
0.027 ? 0.016, 0.060 ? 0.065 and 0.028 ? 0.023 h after
intravenous dose of 1, 2.5 and 5 mg kg−1 columbianadin,
respectively. These results showed that columbianadin
was quickly distributed in the body tissues after intra-
venous administration of columbianadin. The elimin-
ation half-lives (T1/2β) of columbianadin were 0.58 ?
0.20, 0.52 ? 0.25 and 0.52 ? 0.22 h after the dose of 1,
2.5 and 5 mg kg−1, which demonstrated that the elimin-
ation of columbianadin was relatively quick in rats.
These results were higher than the elimination half-life
time (20 min and 29 min) after the dose of 10 and
20 mg kg−1. After intravenous administration of columbia-
nadin at three levels of doses, Cmax and AUC of columbia-
nadin were mainly dependent on the dose with the
coefficient of correlation of 0.986 and 0.920 in the three
groups after intravenous administration, respectively, indi-






SD Remains RSD Remains RSD Accuracy RSD Accuracy RSD
%) (%) (%) (%) (%) (%) (%) (%) (%)
.85 110 5.81 97.3 12.3 91.9 4.02 92.9 4.29
1.1 103 5.37 90.0 6.24 104 4.73 106 6.09
.04 92.6 6.46 99.2 5.62 106 7.2 98.6 7.73
Figure 2 Plasma concentration-time profiles of the columbianadin in rats after three intravenous dose of 1, 2.5 and 5 mg kg−1.
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with previous results that there exists a good dose? effect
relationship of columbianadin in rat body [14]. It was
demonstrated that the present method based on LC-MS
/MS with a LLOQ at 4 ng mL−1 was sensitive enough for
the pharmacokinetics research and could satisfy the re-
quirements of the pharmacokinetics study on columbiana-
din after intravenous administration.Experimental
Chemicals and reagents
Acetonitrile (Dikma technologies Inc, USA) and metha-
nol (Tianjin concord Science Co. Ltd., Tianjin, China)
were of chromatographic grade. Columbianadin and
bergapten (IS) were purchased from National Institute
of the Control of Pharmaceutical and Biological Products
(Beijing, China). Ethyl acetate and ammonium acetate
were of analytical grade. Deionized water was purified
with a Milli-Q Academic ultra-pure water system
(Millipore, Milford, MA, USA), and all other reagents
were of analytical grade (Tianjin Concord Science Co.
Ltd., Tianjin, China).Table 2 Main pharmacokinetic parameters of
columbianadin in rats after intravenous three doses of 1,
2.5 and 5 mg kg−1, respectively
Parameters Low Media High
T1/2α(h) 0.027 ? 0.016 0.060 ? 0.065 0.028 ? 0.023
T1/2β(h) 0.58 ? 0.20 0.52 ? 0.25 0.52 ? 0.22
Cmax(μg/L) 1253 ? 809 2741 ? 1005 4653 ? 2628
AUC(0-tn)(μg/Lh) 459 ? 346 563 ? 124 1294 ? 513
AUC(0-∞)(μg/Lh) 478 ? 365 593 ? 113 1344 ? 529
MRT(0-tn)(h) 1.03 ? 0.19 0.65 ? 0.10 1.22 ? 0.61
MRT(0-∞)(h) 1.28 ? 0.23 0.85 ? 0.25 1.62 ? 0.89Preparation of stock solution, calibration samples and
quality control (QC) samples
The standard stock solutions were prepared by dissolv-
ing appropriate quantities of columbianadin and IS in
amber volumetric flasks to achieve a concentration of
2.0 mg mL−1 and 100 ng mL−1, respectively. The calibra-
tion curves of columbianadin were prepared at the con-
centration levels of 4, 8, 20, 40, 200, 500, 2500, 10000
and 20000 ng mL−1spiking 100 μL blank rat plasma with
10 μL appropriate standard solution of columbianadin
and 10 μL IS. Quality control (QC) samples were pre-
pared following the same sample preparation method
described above at the concentrations of 20, 1000 and
10000 ng mL−1, respectively. The solutions were stored
at 4?C until analysis.
Preparation of sample
The plasma samples (100 μL) were thawed at room
temperature and mixed with 10 μL IS solution (100 ng
mL−1), then extracted with ethyl acetate (1000 μL) and
swirled for 1 min. The supernatant was collected to dryness
in a water bath by using nitrogen at 40?C. The residue was
dissolved with 100 μL methanol, swirled for 1 min and cen-
trifuged at 14000 rpm for 10 min. 15 μL of the supernatant
was injected into the LC? MS/MS system for analysis.
Method validation
The newly established LC-MS/MS method was validated
in terms of specificity, sensitivity, linearity, accuracy, pre-
cision, recovery, matrix effects and stability.
Specificity and sensitivity
The specificity of the method was tested in six different
sources of blank rat plasma and the corresponding
spiked plasma with columbianadin. Each sample was
performed by the same preparation procedure and ana-
lytical conditions mentioned above to ensure no inter-
ference at the retention time of columbianadin and IS.
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The linearity of the newly established method was evalu-
ated by assaying three calibration curves in rat plasma in
the range of 4 ? 20000 ng mL−1. The calibration curves
were achieved by a weighted (1/x2) least squares linear
fitting through the measurement of the peak-area ratios
of columbianadin to IS versus columbianadin levels in
rat plasma. The acceptance criterion for each back-
calculated standard concentration must be within 15%
deviation of the nominal value with the exception of
LLOQ, for which the maximum acceptable deviation
was set at 20%. The correlation coefficient (r) should
also be greater than 0.99. The lower limit of quantifica-
tion (LLOQ) was defined as the lowest concentration in
the standard curve at which the signal-to-noise ratio (S/
N) was preliminarily larger than five, the relative stand-
ard deviation (RSD) (n =6) was within 20%, and the rela-
tive error (RE) was within ?20% [17]. The limit of
detection (LOD) was defined as the concentration with
the signal-to-noise ratio (S/N) was 3:1.
Accuracy and precision
The analytical accuracy and precision were evaluated
by assaying at three QC levels. Six samples of each con-
centration were then carried through the sample prepar-
ation as described above to analyze intra- and inter- batch
(on three consecutive batches) accuracy and precision.
The peak-area ratios of analyte to IS were measured. The
accuracy and precision were calculated by the percentage
value of calculated concentration to known concentration
and the relative standard deviation (RSD), respectively.
For acceptable values, the intra- and inter-batch accuracy
should range from 85% to 115%. The precision at each
concentration was expected to be lower than 15%.
Recovery and matrix effect
The recovery and matrix effects of this method were
evaluated at three levels of QC samples (n =6). The re-
covery of columbianadin was calculated by comparing
the peak areas obtained from spiked plasma samples
with those of peak areas of the analyte spiked post-
treatment at corresponding concentrations. Matrix ef-
fects were performed by comparing the mean peak areas
of the analyte spiked post-treatment to those of the ana-
lyte solutions at corresponding concentrations.
Stability
The stability of columbianadin was examined by analyz-
ing replicates (n = 6) of the three levels of QC samples
under different conditions. The processed stability was
assessed by analyzing samples left in autosampler vials
at ambient temperature for 24 h. Freeze ? thaw stability
was evaluated after three cycles of −20?C to 25?C. Long
term stability was evaluated by placing plasma at −20?Cfor two weeks. Columbianadin was considered to be
stable in various conditions with a deviation of less than
15%.
Application to a pharmacokinetic study in rats
Male Sprague ? Dawley rats (250 ? 280 g) were kept
under controlled environmental conditions with access
to standard laboratory food and water. The rats were
randomly divided into three groups with ten rats in
each group to diminish the individual variation. The
three groups were given columbianadin intravenously
for a dose of 1, 2.5, 5 mg kg−1, respectively. The rat
blood samples (approximately 0.2 mL) were collected
in heparinized 1.5 mL polythene tubes at 0.03, 0.08,
0.17, 0.25, 0.33, 0.5, 0.75, 1, 2, 3, 4, 5, 6 and 8 h from
their fossa orbitalis after intravenous administration.
Then the samples were centrifuged at 4000 rpm for
10 min at 4?C immediately and the supernatant collected.
All the supernatant samples were stored at −20?C and
were brought to room temperature before use.
Data analysis
The pharmacokinetic parameters were carried out by
using two-compartmental analysis for intravenous admin-
istration groups of rats following DAS pharmacokinetic
software package (version 1.0, Chinese Pharmacological
Association, China, Anhui).
Conclusion
In the study, a rapid, sensitive and accurate LC ? MS/
MS method was established and validated for the ana-
lysis of columbianadin in rat plasma after intravenous
administration of columbianadin with a shorter time of
10 min. Compared with a previous HPLC method, one
advantage of the established LC ? MS/MS method is a
green and eco-friendly technique with lower consump-
tion of harmful organic solvents when the large num-
bers of plasma samples should be analyzed. Another
advantage of this method is its high sensitivity with
lower limit of quantification of 4 ng/mL as well as wide
linearity and high specificity. The validated method was
successfully applied to a pharmacokinetic study follow-
ing intravenous administration of pure columbianadin.
The intravenous administration of columbianadin ex-
periment showed that the elimination of columbianadin
was relatively quick and fitted with linear pharmacokin-
etics. It is the first report to evaluate the pharmacokin-
etics of columbianadin by LC-MS/MS.
Methods
LC/MS/MS instrument and analytical conditions
The 1200 Agilent series HPLC and an API 3200 triple
quadrupole mass spectrometer equipped with an elec-
trospray ionization source were used (Concord, Ontario,
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1.4.2 software (AB MDS Sciex). Separations were achieved
using an Eclipse plus C18 (4.6 ? 100 mm, 1.8 μm) column
coupled with a security guard C18 (2.1 ? 12.5 mm, 5 μm)
(Agilent Technologies, USA). The mobile phase was com-
posed of acetonitrile - ammonium acetate aqueous solu-
tion (1 mM, 80:20, v/v). The flow rate was 0.3 mL min−1
in isocratic elution mode for 10 minutes. The injection
volume was 15 μL. The temperature of the column was
set at 25?C.
Bergapten was selected as an internal standard (IS).
The multiple reaction monitoring (MRM) mode was se-
lected to monitor the precursor-to-product ion transi-
tions of m/z 329.3→m/z 229.3 for columbianadin and
m/z 217.2→m/z 202.2 for bergapten (IS) at positive
ionization mode. The optimal instrument parameters of
the mass spectrometer were as follows: Curtain gas,
15 psi; collision gas, 5 psi; ionSpray voltage, 5500 V;
temperature, 350?C; ion source gas1, 40 psi; ion source
gas2, 60 psi. Declustering potential (DP) were set at 81
and 55 V, collision energy (CE) were at 13 and 25 V, en-
trance potential (EP) at 3 and 7 V, the collision cell exit
potential (CXP) both at 20 V for columbianadin and IS,
respectively.
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